Harbour Investments’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$82.1K Sell
1,048
-304
-22% -$20.7K ﹤0.01% 2137
2026
Q1
$87.4K Buy
1,352
+736
+119% +$51.9K ﹤0.01% 2030
2025
Q4
$41.5K Buy
616
+372
+152% +$25K ﹤0.01% 2049
2025
Q3
$17.9K Buy
244
+222
+1,009% +$14.7K ﹤0.01% 2405
2025
Q2
$1.14K Buy
+22
New +$1.25K ﹤0.01% 3256
2023
Q2
– Sell
-720
Closed -$27.5K – 3068
2023
Q1
$27.5K Sell
720
-180
-20% -$8.44K ﹤0.01% 1604
2022
Q4
$51.2K Buy
+900
New +$46.1K ﹤0.01% 1288
2021
Q4
– Sell
-2
Closed – – 3073
2021
Q3
$0 Sell
2
-242
-99% -$10.1K ﹤0.01% 3837
2021
Q2
$11K Buy
244
+38
+18% +$1.68K ﹤0.01% 2673
2021
Q1
$9K Buy
+206
New +$9.4K ﹤0.01% 2660

Other funds holding HALO

Harbour Investments's HALO Position: Q2 2026 in Review

Harbour Investments reduced its Halozyme (HALO) stake by 22% in Q2 2026, selling an estimated $20.7K and leaving 1,048 shares worth $82.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2137.

Harbour Investments first reported a position in HALO in Q1 2021 and has held it in 10 quarters since. The position peaked at $87.4K in Q1 2026. 674 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Harbour Investments held 1,048 shares of Halozyme worth $82.1K as of Q2 2026.
  • Harbour Investments sold 304 Halozyme shares in Q2 2026, an estimated $20.7K.
  • Halozyme made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #2137 holding.
  • Harbour Investments first reported a position in Halozyme in Q1 2021 and has held it in 10 quarters since.
  • Harbour Investments's Halozyme position peaked at $87.4K in Q1 2026.
  • 674 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.